128 related articles for article (PubMed ID: 37606970)
21. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
22. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
Wallace DJ; Ginzler EM; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Petri M; Fettiplace J; Roth DA; Ji B; Heath A
Arthritis Rheumatol; 2019 Jul; 71(7):1125-1134. PubMed ID: 30771238
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
[TBL] [Abstract][Full Text] [Related]
25. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
26. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study.
Sun F; Wu H; Wang Z; Wu T; Wu X; Chen J; Zhang D; Bao C; Shen N; Wu L; Zhu J; Ye S
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979944
[No Abstract] [Full Text] [Related]
28. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
[TBL] [Abstract][Full Text] [Related]
29. Belimumab for systemic lupus erythematosus.
Singh JA; Shah NP; Mudano AS
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010668. PubMed ID: 33631841
[TBL] [Abstract][Full Text] [Related]
30. Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study.
Hunnicutt JN; Fairburn-Beech J; Georgiou ME; Richards A; Gregan YI; Quasny H; Chauhan D
Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36450407
[TBL] [Abstract][Full Text] [Related]
31. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
Wilkinson C; Henderson RB; Jones-Leone AR; Flint SM; Lennon M; Levy RA; Ji B; Bass DL; Roth D
Arthritis Res Ther; 2020 May; 22(1):102. PubMed ID: 32366280
[TBL] [Abstract][Full Text] [Related]
32. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B
Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944
[TBL] [Abstract][Full Text] [Related]
33. Cost Consequence Analysis of Belimumab versus Standard of Care for the Management of Systemic Lupus Erythematosus in Saudi Arabia: A Retrospective Cohort Study.
Alsuwayegh A; Almaghlouth IA; Almasaoud MA; Alzaid AS; Alsuhaibani AA; Almana LH; Alabdulkareem SM; Abudahesh JA; AlRuthia Y
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767283
[TBL] [Abstract][Full Text] [Related]
34. Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study.
Roberts JE; Burn C; Sadun RE; Smitherman EA; Wenderfer SE; Son MBF
Lupus; 2023 Aug; 32(9):1111-1116. PubMed ID: 37410059
[TBL] [Abstract][Full Text] [Related]
35. Belimumab in childhood systemic lupus erythematosus: A review of available data.
Chen F; Zheng Y; Chen X; Wen Z; Xu Y; Yang J; Xu K
Front Immunol; 2022; 13():940416. PubMed ID: 35967351
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
37. The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Bae SC; Bass DL; Chu M; Curtis P; Dimelow R; Harvey L; Ji B; Kurrasch R; Muzaffar S; Punwaney R; Roth DA; Song YW; Xie W; Zhang F
Arthritis Res Ther; 2022 Feb; 24(1):46. PubMed ID: 35172878
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Zheng J; Gu J; Su Y; Li Y; Li X; Xiong C; Cao H; Quasny H; Chu M; Curtis P; DeRose K; Kurrasch R; Meizlik P; Roth DA; Zhang F
Mod Rheumatol; 2023 Jul; 33(4):751-757. PubMed ID: 36208293
[TBL] [Abstract][Full Text] [Related]
39. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study.
Iaccarino L; Andreoli L; Bocci EB; Bortoluzzi A; Ceccarelli F; Conti F; De Angelis R; De Marchi G; De Vita S; Di Matteo A; Emmi G; Emmi L; Gatto M; Gerli R; Gerosa M; Govoni M; Larosa M; Meroni PL; Mosca M; Pazzola G; Reggia R; Saccon F; Salvarani C; Tani C; Zen M; Frigo AC; Tincani A; Doria A
J Autoimmun; 2018 Jan; 86():1-8. PubMed ID: 28935492
[TBL] [Abstract][Full Text] [Related]
40. Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study.
Fernandes BM; Barreira S; Fonseca JE; Cunha M; Santos MJ; Gonçalves N; Fernandes AL; Rodrigues J; Fontes T; Costa L; Bernardes M
Acta Reumatol Port; 2020; 45(3):170-176. PubMed ID: 33139681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
